HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccinees: A phase I randomized trial

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Nilsson, Charlotta ^a,b   Hejdeman, Bo ^b   Godoy Ramirez, Karina ^a   Tecleab, Teghesti ^a   Scarlatti, Gabriella ^c   Bråve, Andreas ^a   Earl, Patricia L ^d   Stout, Richard R ^e   Robb, Merlin L ^f   Shattock, Robin J ^g   Biberfeld, Gunnel ^a,b   Sandström, Eric ^b   Wahren, Britta ^b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Bioject Inc   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DNA VACCINE; ENVELOPE PROTEIN; GAG PROTEIN; GAMMA INTERFERON; GLUCOSE; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS 1 GP160 GAG REVERSE TRANSCRIPTASE REV DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLACEBO; POL PROTEIN; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA CHIANG MAI DOUBLE RECOMBINANT ENCODING HIV 1 ENV GAG POL VACCINE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BLOOD CELL COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CYTOTOXICITY; DRUG DELIVERY DEVICE; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; ELECTROCARDIOGRAM; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INJECTION SITE DISCOMFORT; INJECTION SITE REACTION; JET INJECTOR; LABORATORY DIAGNOSIS; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SWEDISH CITIZEN; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; GENETICS; HIV INFECTIONS; HUMORAL IMMUNITY; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; SWEDEN; VACCINATION; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ELECTROPORATION; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; SWEDEN; VACCINATION; VACCINES, DNA; YOUNG ADULT;

EID: 84938614585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131748     Document Type: Article

References (41)

1. UNAIDS Global Report 2013. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf
2. Kim JH, Rerks-Ngarm S, Excler J-L, Michael NL HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS. 2010; 5:428-434. doi: 10.1097/COH.0b013e32833d17ac PMID: 20978385
3. Excler J-L, Tomaras GD, Russell ND Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS. 2013; 8:421-431. doi: 10.1097/COH.0b013e3283632c26 PMID: 23743791
4. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012; 482:89-93. doi: 10.1038/nature10766 PMID: 22217938
5. Freel SA, Saunders KO, Tomaras GD CD8+ T-cell-mediated control of HIV and SIV infection. Immunol Res. 2011; 49:135-146. doi: 10.1007/s12026-010-8177-7 PMID: 21170741
6. Soghoidan DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. HIV-specific cytolytic CD4 T cell responses during acute infection predict disease outcome. Sci Transl Med. 2012; 4:123ra25. doi: 10.1126/scitranslmed.300165 PMID: 22378925
7. Gaudauin M-C, Yu Y, Barabasz A, Carville A, Piatak M, Lifson JD, et al. Induction of a virus-specific effector-memory CD4+T cell response by attenuated SIV infection. J Exp Med. 2006; 203:2661-2672. PMID: 17116733
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med. 2009; 362:2209-2220.
9. Haynes BF, Gilbert PB, McElrath JM, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Eng J Med. 2012; 366:1275-1286.
10. Zolla Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS ONE. 2014; (9:) 2:e87675. doi: 10.1371/journal.pone.0087572
11. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6, 228ra39. doi: 10.1126/scitranslmed.3007730 PMID: 24648342
12. Gottardo R, Bailer RT, Korber NT, Gnanakaran S, Phillips J, Shen X, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE. 2013; 8(9):e75665. doi: 10.1371/journal.pone.0075665 PMID: 24086607
13. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012; 188:5166-5176. doi: 10.4049/jimmunol.1102756 PMID: 22529301
14. Vasan S Electroporation-mediated administration of candidate DNA vaccines against HIV-1. Methods Mol Biol. 2014; 1121:291-307. doi: 10.1007/978-1-4614-9632-8-26 PMID: 24510833
15. Harari A, Bart P-A, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008; 205:63-77. doi: 10.1084/jem.20071331 PMID: 18195071
16. Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis. 2008; 198:1482-1490. doi: 10.1086/592507 PMID: 18808335
17. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2010; 203:610-619.
18. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, et al. Priming immunization with DNA augments immunogenicity of recombinant Adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE. 2010; 5:e9015. doi: 10.1371/journal.pone.0009015 PMID: 20126394
19. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected east Africans. J Infect Dis. 2010; 201:600-607. doi: 10.1086/650299 PMID: 20078213
20. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, et al. Safety and immunogenicity of an HIV Adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS ONE. 2011; 6:e24517. doi: 10.1371/journal.pone.0024517 PMID: 21931737
21. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011; 28:8417-8428.
22. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE. 2011; 8:e21225. doi: 10.1371/journal.pone.0021225
23. Mehendale S, Thankar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: A phase I randomized trial in HIV-uninfected Indian volunteers. PLoS ONE. 2013; 8:e55831. doi: 10.1371/journal.pone.0055831 PMID: 23418465
24. Liu J, Kjeken R, Mathiesen I, Barouch DH Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation J Virol. 2008; 82:5643-5649. doi: 10.1128/JVI.02564-07 PMID: 18353952
25. Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE. 2009; 4:e7226. doi: 10.1371/journal.pone.0007226 PMID: 19789652
26. Ahlén G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation and infiltration of CD3+ T cells. J Immunol. 2007; 179:4741-4753. PMID: 17878373
27. Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, Ganneru B, et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV and DNA vaccinated macaques. Hum Vaccin Immunother. 2012; 8:1620-1629. doi: 10.4161/hv.21407 PMID: 22894956
28. Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, Bergamaschi C, et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine. 2008; 26:5223-5229. doi: 10.1016/j.vaccine.2008.03.090 PMID: 18468743
29. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS ONE. 2011; 6:e19252. doi: 10.10371/journal.pone.0019252 PMID: 21603651
30. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact on intramuscular electroporation for delivery. J Infect Dis. 2013; 208:818-829. doi: 10.1093/infdis/jit236 PMID: 23840043
31. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine. 2008; 26:440-448. PMID: 18082294
32. Kulkarni V, Rosati M, Bear J, Pilkongton GR, Jalah R, Bergamaschi C, et al. Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. Hum Vaccin Immunother. 2012; 10:2081-2094.
33. Roos A-K, Moreno S, Leder C, Pavlenko M, King A, Pisa P Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther. 2006; 13: 320-327. PMID: 16185933
34. Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1 specific CD8+ T cells and humoral responses in mice. Mol Ther. 2007; 15:1724-1733. PMID: 17579577
35. Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, et al. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. 2009; 27:5885-5895. doi: 10.1016/j.vaccine.2009.07.039 PMID: 19654066
36. Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol. 2000; 74:11367-76. PMID: 11070037
37. Nilsson C, Aboud S, Karlén K, Hejdeman B, Urassa W, Biberfeld G Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin Vaccine Immunol. 2008; 15:585-589. doi: 10.1128/CVI.00161-07 PMID: 18287577
38. Aboud S, Nilsson C, Karlén K, Marovich M, Wahren B, Sandström E, et al. Strong HIV-specific CD4+ and CD8+ T-lymphocytes proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified Vaccinia virus Ankara expressing HIV-1 genes. Clin Vaccine Immunol. 2010; 17:1124-1131. doi: 10.1128/CVI.00008-10 PMID: 20463104
39. Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, et al. Broad and potent cellular and humoral immune responses after a second late HIV-MVA vaccination in HIV-DNA primed and HIV-MVA boosted Swedish vaccinees. AIDS Res Hum Retroviruses. 2014; 30:299-311 doi: 10.1089/aid2013.0149 PMID: 24090081
40. Betts MR, Brenchley JM, Price DA, De Rosa SC, Doueck DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Imm Methods. 2003; 281:65-78.
41. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, et al. International network for comparison of HIV neutralizing assays: the NeutNet report. PLoS ONE. 2009; 4:e4505. doi: 10.1371/journal.pone.0004505 PMID: 19229336